Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis

被引：0
|
作者：
H. J. Nielsen
I. J. Christensen
M. N. Svendsen
U. Hansen
K. Werther
N. Brünner
L. J. Petersen
J. K. Kristensen
机构：
[1] Departments of Surgical Gastroenterology,
[2] Hvidovre Hospital,undefined
[3] University of Copenhagen,undefined
[4] Hvidovre,undefined
[5] Copenhagen,undefined
[6] Denmark,undefined
[7] Fax ++ 45 3632 3760,undefined
[8] e-mail:h.j.nielsen@ofir.dk,undefined
[9] Finsen Laboratory,undefined
[10] 49 Strandboulevarden,undefined
[11] University of Copenhagen,undefined
[12] Copenhagen,undefined
[13] Denmark,undefined
[14] Fax ++ 45 3632 3760,undefined
[15] Departments of Pathology,undefined
[16] Hvidovre Hospital,undefined
[17] University of Copenhagen,undefined
[18] Hvidovre,undefined
[19] Copenhagen,undefined
[20] Denmark,undefined
[21] Fax ++ 45 3632 3760,undefined
[22] Department of Clinical Physiology,undefined
[23] Bispebjerg Hospital,undefined
[24] University of Copenhagen,undefined
[25] Copenhagen,undefined
[26] Denmark,undefined
[27] Fax ++ 45 3632 3760,undefined
[28] Departments of Dermatology,undefined
[29] Hvidovre Hospital,undefined
[30] University of Copenhagen,undefined
[31] Hvidovre,undefined
[32] Copenhagen,undefined
[33] Denmark,undefined
[34] Fax ++ 45 3632 3760,undefined
来源：
Inflammation Research | 2002年 / 51卷
关键词：
Key words: Psoriasis – VEGF – PAI-1 – ranitidine – histamine-2 receptor antagonists – angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective and Design: An evaluation of angiogenesis related molecules during open treatment of psoriasis.¶Materials and Subjects: Plasma samples and skin biopsies from 16 patients with psoriasis and plasma samples from 13 healthy controls.¶Treatment: Ranitidine 300 mg orally twice daily for 6 months.¶Methods: Vascular endothelial growth factor (VEGF) and plasminogen activator inhibitor-1 (PAI-1) were determined by ELISA methods in plasma collected from the patients before treatment and after 1, 3 and 6 months. Vessel counts were performed in biopsies from affected skin areas taken before treatment and after 3 and 6 months. The results were compared to simultaneous PASI scores.¶Results: Pre-treatment plasma levels of VEGF and PAI-1 were significantly elevated in patients compared with levels in healthy persons (p = 0.02 and p = 0.04, respectively). The plasma levels decreased significantly during treatment (p = 0.03 and p = 0.01, respectively), and the decrease in combined levels correlated with the decrease in PASI score. However, the vessel density in affected skin did not change during treatment.¶Conclusions: Increased pre-treatment levels of VEGF and PAI-1 and decrease during improvement of the disease suggest that the two molecules may play a role in pathogenesis of psoriasis.
引用
收藏
页码：563 / 567
页数：4
相关论文
共 50 条
  • [21] Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms
    Kim, Eun Ran
    Yang, Mun Hee
    Lim, Yeun Jung
    Lee, Jin Hee
    Chang, Dong Kyung
    Kim, Young-Ho
    Son, Hee Jung
    Kim, Jae J.
    Rhee, Jong Chul
    Kim, Jin Yong
    GUT AND LIVER, 2013, 7 (05) : 519 - 523
  • [22] The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension
    Çoban, E
    Ozdogan, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) : 541 - 544
  • [23] Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels
    Sakata, Toshiyuki
    Kario, Kazuomi
    ATHEROSCLEROSIS, 2011, 214 (02) : 490 - 491
  • [24] The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis
    Birdane, A
    Haznedaroglu, IC
    Bavbek, N
    Kosar, A
    Büyükasik, Y
    Özcebe, O
    Dündar, SV
    Kirazli, S
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2005, 11 (02) : 197 - 201
  • [25] Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels
    Sakata, T.
    Kario, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 82 - 83
  • [26] Elevated donor plasminogen activator inhibitor-1 levels and the risk of primary graft dysfunction
    Hamilton, Barbara C. S.
    Dincheva, Gabriela R.
    Zhuo, Hanjing
    Golden, Jeffrey A.
    Brzezinski, Marek
    Singer, Jonathan P.
    Matthay, Michael A.
    Kukreja, Jasleen
    CLINICAL TRANSPLANTATION, 2018, 32 (04)
  • [27] PLASMINOGEN-ACTIVATOR INHIBITOR-1 LEVELS IN PLASMA ARE ASSOCIATED WITH INSULIN RESISTANCE
    VANLOON, BJP
    KLUFT, C
    RADDER, JK
    BLANKENSTEIN, MA
    MEINDERS, AE
    DIABETOLOGIA, 1992, 35 : A9 - A9
  • [28] Determinants of plasma levels of plasminogen activator inhibitor-1 - A study of normotensive twins
    Cesari, M
    Sartori, MT
    Patrassi, GM
    Vettore, S
    Rossi, GP
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) : 316 - 320
  • [29] PLASMINOGEN-ACTIVATOR INHIBITOR-1 PLASMA-LEVELS AND CORONARY RESTENOSIS
    HUBER, K
    BINDER, BR
    CIRCULATION, 1992, 86 (05) : 1661 - 1662
  • [30] The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis
    Birdane, A
    Haznedaroglu, IC
    Özath, D
    Sayinalp, N
    Kosar, A
    Büyükasik, Y
    Özcebe, O
    Karakus, S
    Dündar, SV
    Kirazli, S
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 120 - 120
12345